A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2018
|
| Sorozat: | IMMUNOTHERAPY
10 No. 2 |
| doi: | 10.2217/imt-2017-0107 |
| mtmt: | 3298537 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/15422 |
| Tartalmi kivonat: | The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however, the approval was based on randomized clinical trials conducted in patients with rheumatoid arthritis and ankylosing spondylitis. In the past 2-3 years, new findings from prospective observational studies supported the short-, medium- and long-term clinical efficacy and safety of CT-P13 in patients with IBD. This review summarized the clinical use and efficacy of the first biosimilar IFX, CT-P13, in the treatment of IBD. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 107-117 |
| ISSN: | 1750-743X |